Laurence W. Busse

Angiotensin II for the Treatment of Vasodilatory Shock

Ashish K. Khanna, Shane English, Xueyuan S. Wang et al. · New England Journal of Medicine · 2017 · 879 citations · Full text

Pharmacy, Pharmacotherapy, Cardiovascular Pharmacotherapy +14

Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity

Mark W. Tenforde, Wesley H. Self, Katherine Adams et al. · JAMA · 2021 · 681 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +12

Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study

Adam S. Lauring, Mark W. Tenforde, James D. Chappell et al. · BMJ · 2022 · 681 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions — United States, March–August 2021

Wesley H. Self, Mark W. Tenforde, Jillian P. Rhoads et al. · MMWR Morbidity and Mortality Weekly Report · 2021 · 455 citations · Full text

Veterinary Medicine, Infectious Diseases, Preventive Medicine +16

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II

James A. Tumlin, Raghavan Murugan, Adam M. Deane et al. · Critical Care Medicine · 2018 · 293 citations · Full text

Medicine, Nephrology, Pharmacotherapy +15